NCT04635683 2022-09-30Lenalidomide, Umbralisib, and Ublituximab for the Treatment of Relapsed or Refractory Indolent Non-Hodgkin Lymphoma or Mantle Cell LymphomaOhio State University Comprehensive Cancer CenterPhase 1 Withdrawn